» Articles » PMID: 34885099

Analysis of Circulating Tumour Cells in Early-Stage Uveal Melanoma: Evaluation of Tumour Marker Expression to Increase Capture

Abstract

(1) Background: The stratification of uveal melanoma (UM) patients into prognostic groups is critical for patient management and for directing patients towards clinical trials. Current classification is based on clinicopathological and molecular features of the tumour. Analysis of circulating tumour cells (CTCs) has been proposed as a tool to avoid invasive biopsy of the primary tumour. However, the clinical utility of such liquid biopsy depends on the detection rate of CTCs. (2) Methods: The expression of melanoma, melanocyte, and stem cell markers was tested in a primary tissue microarray (TMA) and UM cell lines. Markers found to be highly expressed in primary UM were used to either immunomagnetically isolate or immunostain UM CTCs prior to treatment of the primary lesion. (3) Results: TMA and cell lines had heterogeneous expression of common melanoma, melanocyte, and stem cell markers. A multi-marker panel of immunomagnetic beads enabled isolation of CTCs in 37/43 (86%) patients with UM. Detection of three or more CTCs using the multi-marker panel, but not MCSP alone, was a significant predictor of shorter progression free ( = 0.040) and overall ( = 0.022) survival. (4) Conclusions: The multi-marker immunomagnetic isolation protocol enabled the detection of CTCs in most primary UM patients. Overall, our results suggest that a multi-marker approach could be a powerful tool for CTC separation for non-invasive prognostication of UM.

Citing Articles

[Circulating tumor cells in uveal melanoma : "The needle in the haystack"].

Grisanti S, Sonntag S, Tura S Ophthalmologie. 2024; 121(12):954-962.

PMID: 39580374 DOI: 10.1007/s00347-024-02136-z.


Recent Advances in Molecular and Genetic Research on Uveal Melanoma.

Fuentes-Rodriguez A, Mitchell A, Guerin S, Landreville S Cells. 2024; 13(12.

PMID: 38920653 PMC: 11201764. DOI: 10.3390/cells13121023.


Heterogeneity and molecular landscape of melanoma: implications for targeted therapy.

Beigi Y, Lanjanian H, Fayazi R, Salimi M, Hoseyni B, Noroozizadeh M Mol Biomed. 2024; 5(1):17.

PMID: 38724687 PMC: 11082128. DOI: 10.1186/s43556-024-00182-2.


Advancements in Circulating Tumor Cell Research: Bridging Biology and Clinical Applications.

Salu P, Reindl K Cancers (Basel). 2024; 16(6).

PMID: 38539545 PMC: 10969710. DOI: 10.3390/cancers16061213.


Assessment of Different Circulating Tumor Cell Platforms for Uveal Melanoma: Potential Impact for Future Routine Clinical Practice.

Martel A, Mograbi B, Romeo B, Gastaud L, Lalvee S, Zahaf K Int J Mol Sci. 2023; 24(13).

PMID: 37446253 PMC: 10342234. DOI: 10.3390/ijms241311075.


References
1.
Blum E, Yang J, Komatsubara K, Carvajal R . Clinical Management of Uveal and Conjunctival Melanoma. Oncology (Williston Park). 2016; 30(1):29-32, 34-43, 48. View

2.
Freeman J, Gray E, Millward M, Pearce R, Ziman M . Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells. J Transl Med. 2012; 10:192. PMC: 3480925. DOI: 10.1186/1479-5876-10-192. View

3.
Eisenstein A, Gonzalez E, Raghunathan R, Xu X, Wu M, McLean E . Emerging Biomarkers in Cutaneous Melanoma. Mol Diagn Ther. 2018; 22(2):203-218. DOI: 10.1007/s40291-018-0318-z. View

4.
Aya-Bonilla C, Morici M, Hong X, McEvoy A, Sullivan R, Freeman J . Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells. Br J Cancer. 2020; 122(7):1059-1067. PMC: 7109152. DOI: 10.1038/s41416-020-0750-9. View

5.
Robertson A, Shih J, Yau C, Gibb E, Oba J, Mungall K . Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell. 2017; 32(2):204-220.e15. PMC: 5619925. DOI: 10.1016/j.ccell.2017.07.003. View